CD274 and non-small cell lung carcinoma: Atezolizumab, an anti-programmed cell death-ligand 1 (PD-L1) antibody, is a widely used ICI that is part of standard therapy in non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and HCC, and second-line therapy in other cancerous diseases.